Brain Metastasis

Cabozantinib demonstrated intracranial activity and appeared safe among patients with renal cell carcinoma and brain metastases, according to a study in JAMA Oncology.

In this video, Sara Tolaney, MD, MPH, assistant professor of medicine at Harvard Medical School and a breast medical oncologist with Dana-Farber Cancer Institute, discusses research being presented at the symposium.

In a video interview, Nancy U. Lin, MD, discussed the DESTINY-Breast12 trial in progress presented at the virtual ESMO Congress.

The addition of nivolumab and ipilimumab to first-line chemotherapy conferred durable survival benefits to patients with advanced non-small cell lung cancer and brain metastases, according to results of the phase 3 CheckMate 9LA trial.

About 4% of patients with advanced renal cell carcinoma had asymptomatic brain metastases, according to results of a retrospective multi-institutional cohort study published in Journal of the National Comprehensive Cancer Network.

Manmeet Ahluwalia, MD, FACP, MBA, has been appointed deputy director of Baptist Health’s Miami Cancer Institute.

Conventional whole-brain radiotherapy (WBRT) has changed little and remained an important part of the armamentarium in the management of brain metastases for the better part of the past half century. WBRT is a proven effective therapy but has well-established toxicity, including both short-term effects, such as fatigue and hair loss, as well as long-term effects, which are primarily neurocognitive.

Stereotactic radiosurgery conferred equivalent OS as whole-brain radiation but with less cognitive decline in patients with four or more nonmelanoma brain metastases, according to study results presented at the virtual ASTRO Annual Meeting.

Local hypofractionated stereotactic radiotherapy to the resection cavity demonstrated a favorable risk-benefit profile among patients with brain metastases, according to results of an international, multicenter cohort study.

T-DMI induced clinically meaningful antitumor activity among patients with HER2-positive metastatic breast cancer and brain metastases, according to an exploratory analysis of the KAMILLA trial published in Annals of Oncology.